106 related articles for article (PubMed ID: 20807524)
1. Effect of non-genetic factors on paraoxonase 1 activity in patients undergoing hemodialysis.
Rajković MG; Rumora L; Juretić D; Grubisić TZ; Flegar-Mestrić Z; Vrkić N; Sinjeri Z; Barisić K
Clin Biochem; 2010 Dec; 43(18):1375-80. PubMed ID: 20807524
[TBL] [Abstract][Full Text] [Related]
2. Serum paraoxonase activity in uremic predialysis and hemodialysis patients.
Dirican M; Akca R; Sarandol E; Dilek K
J Nephrol; 2004; 17(6):813-8. PubMed ID: 15593056
[TBL] [Abstract][Full Text] [Related]
3. Paraoxonase activity in glomerulonephritic patients.
Gullulu M; Kahvecioglu S; Dirican M; Akdag I; Ocak N; Demircan C; Dilek K; Ersoy A; Yavuz M; Yurtkuran M
Ren Fail; 2007; 29(4):433-9. PubMed ID: 17497465
[TBL] [Abstract][Full Text] [Related]
4. Paraoxonase activity in healthy, diabetic, and hemodialysis patients.
Gbandjaba NY; Ghalim N; Hassar M; Berrougui H; Labrazi H; Taki H; Saile R; Khalil A
Clin Biochem; 2012 Apr; 45(6):470-4. PubMed ID: 22285382
[TBL] [Abstract][Full Text] [Related]
5. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.
Gugliucci A; Mehlhaff K; Kinugasa E; Ogata H; Hermo R; Schulze J; Kimura S
Clin Chim Acta; 2007 Feb; 377(1-2):213-20. PubMed ID: 17118352
[TBL] [Abstract][Full Text] [Related]
6. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
[TBL] [Abstract][Full Text] [Related]
7. Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease.
Sztanek F; Seres I; Harangi M; Lőcsey L; Padra J; Paragh GJ; Asztalos L; Paragh G
Nephrol Dial Transplant; 2012 Jul; 27(7):2866-72. PubMed ID: 22247228
[TBL] [Abstract][Full Text] [Related]
8. Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke.
Can Demirdöğen B; Türkanoğlu A; Bek S; Sanisoğlu Y; Demirkaya S; Vural O; Arinç E; Adali O
Clin Biochem; 2008 Jan; 41(1-2):1-9. PubMed ID: 17920578
[TBL] [Abstract][Full Text] [Related]
9. Discordance in human paraoxonase-1 gene between phenotypes and genotypes in chronic kidney disease.
Paragh G; Seres I; Harangi M; Pocsai Z; Asztalos L; Locsey L; Szeles G; Kardos L; Varga E; Karpati I; Adany R
Nephron Clin Pract; 2009; 113(1):c46-53. PubMed ID: 19602899
[TBL] [Abstract][Full Text] [Related]
10. Arylesterase and paraoxonase activity of paraoxonase (PON1) affected by ischemia in the plasma of patients with arterial occlusion of the lower limbs.
Kasprzak M; Iskra M; Majewski W; Wielkoszyński T
Clin Biochem; 2009 Jan; 42(1-2):50-6. PubMed ID: 18976644
[TBL] [Abstract][Full Text] [Related]
11. Variation in paraoxonase-1 activity and atherosclerosis.
Soran H; Younis NN; Charlton-Menys V; Durrington P
Curr Opin Lipidol; 2009 Aug; 20(4):265-74. PubMed ID: 19550323
[TBL] [Abstract][Full Text] [Related]
12. Activity of paraoxonase 1 (PON1) on HDL
Miljkovic M; Stefanovic A; Vekic J; Zeljkovic A; Gojkovic T; Simic-Ogrizovic S; Bogavac-Stanojevic N; Cerne D; Ilic J; Stefanovic I; Jelic-Ivanovic Z; Spasojevic-Kalimanovska V; Kotur-Stevuljevic J
Clin Biochem; 2018 Sep; 60():52-58. PubMed ID: 30130521
[TBL] [Abstract][Full Text] [Related]
13. Paraoxonase (PON1) polymorphism and activity as the determinants of sensitivity to organophosphates in human subjects.
Sirivarasai J; Kaojarern S; Yoovathaworn K; Sura T
Chem Biol Interact; 2007 Jul; 168(3):184-92. PubMed ID: 17532308
[TBL] [Abstract][Full Text] [Related]
14. Biochemical, environmental, and genetic factors associated with paraoxonase (PON1) activity.
Sirivarasai J; Kaojarern S; Sura T; Yoovathaworn K
Biochem Genet; 2011 Jun; 49(5-6):364-8. PubMed ID: 21258965
[No Abstract] [Full Text] [Related]
15. Paraoxonase 1 arylesterase activity and mass are reduced and inversely related to C-reactive protein in patients on either standard or home nocturnal hemodialysis.
Kannampuzha J; Darling PB; Maguire GF; Donnelly S; McFarlane P; Chan CT; Connelly PW
Clin Nephrol; 2010 Feb; 73(2):131-8. PubMed ID: 20129020
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms and activity of PON1 in a Mexican population.
Rojas-García AE; Solís-Heredia MJ; Piña-Guzmán B; Vega L; López-Carrillo L; Quintanilla-Vega B
Toxicol Appl Pharmacol; 2005 Jun; 205(3):282-9. PubMed ID: 15922013
[TBL] [Abstract][Full Text] [Related]
17. Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients.
Gugliucci A; Lunceford N; Kinugasa E; Ogata H; Schulze J; Kimura S
Clin Chim Acta; 2007 Sep; 384(1-2):105-12. PubMed ID: 17632094
[TBL] [Abstract][Full Text] [Related]
18. Paraoxonase phenotype distribution in a healthy Iranian population.
Sepahvand F; Shafiei M; Ghaffari SM; Rahimi-Moghaddam P; Mahmoudian M
Basic Clin Pharmacol Toxicol; 2007 Aug; 101(2):104-7. PubMed ID: 17651311
[TBL] [Abstract][Full Text] [Related]
19. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
[TBL] [Abstract][Full Text] [Related]
20. Oxidant and antioxidant of arylesterase and paraoxonase as biomarkers in patients with hepatitis C virus.
Ali EM; Shehata HH; Ali-Labib R; Esmail Zahra LM
Clin Biochem; 2009 Sep; 42(13-14):1394-400. PubMed ID: 19538950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
